Viyash Scientific Acquired BioForLife Italia
The firm purchased the Milan-based pet-care company for approximately ₹188 crore.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you believe domestic companies expanding internationally provides a net benefit to your country?
Viyash Scientific has completed its acquisition of 100% of the shares in Milan-based pet-care firm BioForLife Italia. The transaction was finalized for a total cost of approximately ₹188 crore.
Why it matters
The deal allows Viyash Scientific to expand its footprint in the international pet-care sector through its step-down subsidiary, Alivira Animal Health Limited.
Viyash Scientific secured a full 100% shareholding in BioForLife Italia for a total consideration of ₹188 crore. The process included comprehensive legal, financial, and tax due diligence conducted by BDO Italy.
The players
Viyash Scientific
This Indian company is a firm focused on health products that has recently expanded into the pet-care market.
BioForLife Italia
Based in Milan, Italy, this organization specializes in pet-care products.
DSK Legal
This law firm provides advisory services for corporate transactions and structured this specific acquisition.
Alivira Animal Health Limited
A subsidiary operating out of Ireland that functioned as the vehicle for this acquisition.
BDO Italy
This professional services firm performed the necessary due diligence for the transaction.
The details
DSK Legal advised Viyash Scientific throughout the transaction, handling the drafting and negotiation of the share purchase agreement during meetings in Milan. The acquisition successfully satisfied requirements under Italian FDI and Golden Power Regulations.
Timeline
The acquisition transaction was officially closed on October 1, 2026.
Market Landscape
This acquisition follows the increasing trend of Indian healthcare firms acquiring established European companies to bolster their global pet-care portfolios. It demonstrates a clear shift toward international consolidation to compete with major multi-national pet-health entities.
Customers of BioForLife Italia should see no immediate changes to their product availability or current brand offerings following this transaction. Long-term impacts on pricing or product lines remain subject to future management decisions made by the new parent company.
The takeaway
This acquisition underscores the aggressive expansion strategy of Indian firms into the European pet-health market. Investors and stakeholders should monitor how the integration of Italian manufacturing assets influences the parent company's future quarterly performance.
Further reading
For more information on industry trends, visit the /business/industry/healthcare/ section.
Source note: This article includes information reported by Bar and Bench - Indian Legal news.
Live Poll
Do you believe domestic companies expanding internationally provides a net benefit to your country?
